Our results may also apply to distinct AML subsets since no significant difference was observed in the MBD2 expression pattern among different cytogenetic/molecular AML subgroups according to the analysis of a web-based and repository of data from the Oncomine and Bloodspot databases. This evidence concerns the gene MBD2 and acute myeloid leukemia.